Venlafaxine (Dosage)

Venlafaxine is a serotonin reuptake inhibitor drug used to treat depression. Identifying polymorphisms of genes involved in the metabolism of venlafaxine, such as the CYP2D6 gene, may allow establishing a better adjustment of the dose of this treatment in order to obtain better effects.

Venlafaxine potentiates monoaminergic activity in the central nervous system (CNS). In preclinical studies it has been proven that venlafaxine and its main metabolite, O-desmetilvenlafaxina, are potent inhibitors of the reuptake of serotonin and noradrenaline (SNRI). It also weakly inhibits dopamine reuptake.

CONTRAINDICATIONS

Hypersensitivity to venlafaxine.

Concomitant prescription with MAOI antidepressants is contraindicated. Do not initiate the treatment with venlafaxine until 14 days after the interruption of MAOI treatment and stop treatment with venlafaxine for at least 7 days before initiating the MAOI treatment.

CAUTIONS

Precautions should be taken when prescribing venlafaxine in patients with a recent history of infarction or unstable heart disease, a history of seizures, in patients whose conditions may be compromised by increases in heart rate, in patients with IOP (elevated intraocular pressure) or at risk of sharp angle glaucoma. Caution in patients with a family history or background of bipolar disorder, history of aggression.

In patients with bleeding disorders or predisposition to them extreme precautions when prescribing venlafaxine together with anticoagulants, drugs that affect platelet function or increase the risk of bleeding. Caring for individuals with kidney failure, liver failure, elderly patients, children under 18 years old and diabetics.

Periodic control of blood pressure is recommended when taking venlafaxine. Hyponatremia and/or syndrome of inappropriate secretion of ADH (antidiuretic hormone) may occur, usually in volume depleted or dehydrated patients.

It is necessary to carry out a rigorous control in patients with a history of suicidal behavior and those who present a significant degree of suicidal ideation prior to start the treatment, since the risk of suicidal thoughts or suicide attempts during the treatment is greater. Gradually reduce the dose over a period of weeks or months to avoid withdrawal reactions.

Assess benefit/risk if akathisia/psychomotor agitation appears. It is recommended to monitor cholesterol levels. Risk of serotonin syndrome, particularly with the concomitant use of other serotonergic agents or that affect the metabolism of serotonin. If the concomitant treatment is clinically justified, is mandatory a strict monitoring of the patient, especially at the beginning and when increasing the dose. Concomitant use with serotonergic precursors (tryptophan supplements), with antipsychotics or with other dopamine antagonists is not recommended.

Consider risk/benefit in patients with high risk of severe cardiac arrhythmia or prolongation of the QTc interval. Avoid concomitant administration with medications that prolong the QTc interval.

SIDE EFFECTS

Asthenia, chills, fatigue, hypertension, vasodilation, palpitations, decreased appetite, constipation, nausea, vomiting, xerostomia, dyspepsia, hypercholesterolemia, weight loss, abnormal dreams, decreased libido, dizziness, dry mouth, headache, hypertonia, insomnia, nervousness, paresthesia, sedation, somnolence, tremor, confusion, depersonalization, yawning, sweating, accommodation abnormalities, mydriasis, visual disturbances, tinnitus, ejaculation/abnormal orgasms in males, anorgasmia, erectile dysfunction, involvement in urination, disorders menstrual, dysuria, and pollakiuria.

PHARMACOLOGIC INTERACTIONS

Potentiation of toxicity with risk of serotonin syndrome if venlafaxine is administered together with triptans, SSRI antidepressants, ISRN antidepressants, lithium, sibutramine, fentanyl and its analogues, dextromethorphan, tapentadol, pethidine, methadone, pentazocine, St. John's wort and drugs that affect the metabolism or serotonin precursors.

Venlafaxine potentiates the effect of warfarin.

The action of venlafaxine is increased by cimetidine.

Venlafaxine potentiates the action and toxicity of haloperidol.

Caution in co-administration with imipramine and metoprolol.

There is an increased risk of QTc prolongation and/or ventricular arrhythmias if venlafaxine is administered together with drugs that prolong the QTc interval (class Ia and III antiarrhythmics: quinidine, amiodarone, sotalol, dofetilide, some antipsychotics such as thioridazine, some macrolide antibiotics, some antihistamines; some quinolone antibiotics such as moxifloxacin).

Avoid alcohol consumption during the treatment.

BRAND NAMES

  • Arafaxina Retard ®
  • Conervin Retard ®
  • Dislaven Retard ®
  • Dobupal ®
  • Flaxen ®
  • Levest ®
  • Vandral ®
  • Venlabrain Retard ®
  • Venlamylan ®
  • Venlapine ®
  • Zarelis ®

Genes analyzed

CYP2D6

Bibliography

Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023 Jul;114(1):51-68.

Frederiksen T. Using population pharmacokinetic analyses of drugs metabolized by CYP2D6 to study the genotype-phenotype translation. Basic Clin Pharmacol Toxicol. 2023 Aug;133(2):113-123.

What do your genes say about you? Start your journey today.

Get a special 5% discount on your first kit.

Haven't you taken our DNA test yet?

Get your genetic test and discover what your DNA says about you.

pack
Starter DNA test
The best option to get started

Ancestry service, Traits and Wellness

Buy
pack
DNA test Advanced DNA test
Know your DNA in depth

Health, Ancestry service, Traits and Wellness

Buy
pack
Genetic analysisUltra
Whole Genome Sequencing 30x

Health, Ancestrality, Traits and Wellness

includes three months of tellmeGen+

Buy

Important information and limitations

Europe
Austria
Belgium
Czech Republic
Denmark
Finland
Germany
Hungary
Ireland
Italy
Netherlands
Norway
Poland
Portugal
Romania
Spain
Sweden
Switzerland
United Kingdom
Asia
Kazakhstan
Saudi Arabia
UAE
America
Brazil
Canada
Chile
Colombia
Mexico
Panama
Peru
United States
Oceania
Australia
The Best Prices of the Year! Only until November 27 Use our coupon BLACK15
Buy